Ингибиторы тирозинкиназы рецептора эпидермального фактора роста: похожие, но разные?

1. Salomon DS, Brandt R, Ciardiello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183–232.
2. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160–74.
3. Normano N, Bianco C, De La, Maiello MR et al. Target-based agents against ErbB receptors and their ligands; a novel approach to cancer treatment. Endocr Relat Cancer 2003; 10: 1–21.
4. Shepherd FA, Rodrigues PJ, Ciuleanu T et al. Erlotonib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–32.
5. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer results fr om a randomized, placebo-controlled, multicenter study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527–37.
6. Blackhall F, Ranson M, Thatcher N. Wh ere next for gefitinib in patients with lung cancer? Lancet Oncol 2006; 7: 499–507.
7. Sharma SV, Bell DW, Settleman J et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169–81.
8. Kim ES, Hirch V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008; 372: 1809–18.
9. Mok T, Wu YL, Thongprasert S et al. Phase III randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer [abstract]. Ann Oncol 2008; 19 (8): viii1,LBA2.
10. Stamos J, Siwkowski MX, Eigenbrot C et al. Structure of the epidermal growth factor receptor kinase domain alone and in the complex with a 4-anilinoqunazoline inhibitor. J Biol Chem 2002; 277: 46265–72.
11. Yun CH, Boggon TJ, Woo MS et al. Structure of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007; 11: 217–27.
12. Speake G, Anderton J, Acheson K et al. A pharmacological comparison of gefitibin (Iressa) and erlotinib. Poster 3784 presented at 97th American Association of Cancer Research Annual Meeting, Washington, DC, USA, 1–5 April 2006.
13. Pollack VA, Savage DM, Baker DA et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291: 739–48.
14. Vallera-Garcia M, Acheson K, Marshall GB et al. Role of EGFR but not HER2 or HER3 gene copy number in predicting sensitivity of neck and head squamous cell carcinoma (SCCHN) cell lines to EGFR tyrosine kinase inhibitors. Poster 6063 presented at the 43rd Annual Meeting of American Society of Clinical Oncology, Chicago, Illinois, 1–5 June 2007.
15. Wakeling AE, Guy SP, Woodburn JR et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62: 5749–54.
16. Moyer JD, Barbacci EG, Iwata KK et al. Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57: 4838–48.
17. Swaisland HC, Smith RP, Laight A et al. Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet 2005; 44: 1165–77.
18. Frohna P, Lu J, Eppler S et al. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol 2006; 46: 282–90.
19. Ling J, Fettner S, Lum BL et al. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs 2008; 19: 209–16.
20. Astra Zeneca. Iressa international Prescribing information. 2005.
21. Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267–79.
22. Johnson JR, Cohen M, Sridhara R et al. Approval summary of erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res; 2005; 11: 6414–21.
23. Lu JF, Eppler SM, Wolf J et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006; 80: 135–45.
24. Rudin C, Liu W, Desai A et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clon Oncol 2008; 26: 1119–27.
25. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor tyrosine-kynase inhibitor, is well tolerate and active in patients with solid, malignant tumors: results og a phase I trial. J Clin Oncol 2002; 20: 2240–50.
26. European Medicines Agency. European Public Assessment Report Tarceva Scientific Discussion. 2008. Available at: http//www.emea.europa.eul.
27. McKillop D, McCormick AD, Millar A et al. Cytochrome P450-dendent metabolism of gefitinib. Xenobiotica 2005; 35: 39–50.
28. Li J, Zhao M, He P et al. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007; 13: 3731–7.
29. McKillop D, Hutchison M, Partridge EA et al. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica 2004; 34: 917–34.
30. Ling J, Johnson KA, Miao Z et al. Metabolism and excretion of erlotonob, a small molecule inhibitor of epidermal growth factor receptor tyrosine kynase, in healthy male volunteers. Drug Metab Dispos 2006; 34: 420–6.
31. Hamilton M, Wolf JL, Rusk J et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006; 12: 2166–71.
32. Swaisland HC, Ranson M, Smith RP et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, intraconazole and metoprolol. Clin Pharmacokinet 2005; 44: 1067–81.
33. Abbas R, Fettner S, Riek M et al. A drug-dryg interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, erlotinib, in healthy subjects. Proc Am Soc Clin Oncol 2003; 22: 548.
34. Rakhit A, Pantze MP, Fettner S et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 2008; 64: 31–41.
35. Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetics, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20: 4292–302.
36. Herbst RS, Maddox AM, Rothenberg ML et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well tolerated and has activity in non-small cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20: 3815–25.
37. OSI Pharmaceuticals Inc TARCEVA Prescribing information. 2008.
38. McKillop D, Partridge EA, Kemp JV et al. Tumor penetration of gefitinib (Iressa)/ an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther 2005; 4: 641–9.
39. Haura E, Sommers E, Becker D et al. Pilot phase II study of preoperative gefitinib in early stage non-small cell lung cancer with assessment of intratumor gefitinib levels and tumor target modulation [abstract]. J Clin Oncol 2007; 25 (18S): 7603.
40. Petty WJ, Dragnev KH, Memoli VA et al. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancer. Clin Cancer Res 2004; 10: 7547–54.
41. Wolf M, Swaisland H, Averbuch S. Development of the novel biologically anticancer agent gefitinib: determining the optimum dose of clinical efficacy. Clin Cancer Res 2004; 10: 4607–4613.
42. Albanell J, Rojo F, Averbuch S et al. Pharmacodynamic studies of the epidermal growth factor inhibitor ZD1839 in skin from cancer patients: histopatologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20: 110–24.
43. Calvo E, Malik SN, Siu LL et al. Assessment of erlotinib pharmacodynamics in tumor and skin of patients with head and neck cancer. Ann Oncol 2007; 18: 761–7.
44. Nakagawa K, Tamura T, Negoro S et al. Phase I Pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib («Iressa» ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003; 14: 922–30.
45. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randimized phase II trial of gefitinib for previosly treated patienys with advanced non-small cell lung cancer. J Clin Oncol 2003; 21: 2237–46.
46. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kynase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 2003; 290: 2149–58.
47. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib with combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: 1545–52.
48. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial – INTACT 1. J Clin Oncol 2004; 22: 777–84.
49. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004; 22: 785–94.
50. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 2005; 23: 5892–9.
51. Bailey LR, Kris M, Wolf M et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib («Iressa» ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2 (abstract). Proc Am Assoc Cancer Res 2003; 44: 1362. LB-170.
52. Giaccone G, Iacona RB, Fandi A et al. Epidermal groath factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. J Cancer Res Clin Oncol 2009; 135: 467–76.
53. Hirsch FR, Varella-Garcia M, Bunn Jr PA et al. Molecular predictors of outcome with gefitinib in a Phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5034–42.
54. Tsao M-S, Sakurada A, Cutz J-C et al. Erlotinib on lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133–44.
55. Perez-Soler R, Van CE. Clinical research of EGFR inhibitors and related dermatologic toxicities. Oncology (Williston Park) 2007; 21: 10–6.
56. Wacker B, Nagrani T, Weinberg J et al. Correlation between devepopment of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III study. Clin Cancer Res 2007; 13: 3913–21.
57. Mita CA, Schwartz G, Mita MM et al. A Pilot pharmacokinetic (PK), anf Pharmacodynamic (PD) study to determine the feasibility of intrapatient dose escalation to tolerate rash and the activity of maximal doses of erlotinib (E) ion previosly treated patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2005; 23 (16): 3045.
58. Dudeck AZ, Kmak KL, Koopmeiners J et al. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previosly treated advanced or metastatic non-small cell lung cancer. Lung Cancer 2006; 51: 89–96.
59. West HL, Franklin WA, McCoy J et al. Gefitinib therapy in advanced bronchioalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 2006; 24: 1807–13.
60. Mohamed MK, Ramalingam S, Lin Y et al. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol 2005; 16: 780–5.
61. Fukuoka M, Kris M, Giaccone G et al. Phase II trials of gefitinib (‘Iressa’, ZD1839): rapid and durable objective responses in patients with advanced non-small cell lung cancer (IDEAL 1and IDEAL 2). Poster presented at the World Congress on Lung Cancer. Canada: Vancouver; 2003.

М.Б.Бычков, С.А.Большакова, Ю.М.Бычков

ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва